Search Within

Gabriella D'Andrea-Carlino

  1. "Biostatistics Service"
Formats
  1. Journal Article (24)
  2. Meeting Abstract (24)
Groups
  1. Biostatistics Service (48)
  2. Breast Medicine Service (48)
  3. Department of Medicine (48)
  4. Epidemiology and Biostatistics (48)
  5. Solid Tumor Oncology Division (48)
  6. Survivorship Research (48)

More Groups

People
  1. Clifford Hudis (45)
  2. Larry Norton (32)
  3. Diana Lake (29)
  4. Sujata Patil (27)
  5. Monica Fornier (26)
  6. Shanu Modi (23)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2018 (1)
  4. 2017 (1)
  5. 2016 (2)
  6. 2015 (4)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Cancer Research (9)
  3. Clinical Cancer Research (8)
  4. Breast Cancer Research and Treatment (7)
  5. Clinical Breast Cancer (6)
  6. Journal of the American Geriatrics Society (2)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. American Society of Clinical Oncology (12)
  3. Springer (7)
  4. Elsevier Inc. (6)
  5. Oxford University Press (2)
  6. Wiley Blackwell (2)

More Publishers

Results (48)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Journal Article

    Gajria, D.; Gonzalez, J.; Feigin, K.; Patil, S.; Chen, C.; Theodoulou, M.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; more...
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save
  • TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR-metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Tolaney, S. M.; Isakoff, S. J.; Ingle, J. N.; Liu, M. C.; Carey, L. A.; Blackwell, K. L.; Rugo, H. S.; Nabell, L.; Abbruzzi, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save